MIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55
TipRanks (Mon, 23-Mar 9:41 AM ET)
ACCESS Newswire (Mon, 23-Mar 9:00 AM ET)
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2
ACCESS Newswire (Wed, 4-Mar 8:00 AM ET)
ACCESS Newswire (Tue, 3-Feb 7:30 AM ET)
Market Chameleon (Thu, 16-Oct 5:54 AM ET)
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Mira Pharmaceuticals trades on the NASDAQ stock market under the symbol MIRA.
As of March 23, 2026, MIRA stock price climbed to $1.13 with 254,907 million shares trading.
MIRA has a beta of 2.50, meaning it tends to be more sensitive to market movements. MIRA has a correlation of 0.25 to the broad based SPY ETF.
MIRA has a market cap of $47.32 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that MIRA belongs to (by Net Assets): VXF, VTI.
MIRA has underperformed the market in the last year with a price return of -7.4% while the SPY ETF gained +17.8%. MIRA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.7% and -2.6%, respectively, while the SPY returned -3.5% and -2.3%, respectively.
MIRA support price is $.87 and resistance is $.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIRA shares will trade within this expected range on the day.